Drug Discovery Today 2012 v.17 №03-04

London, UK.: Elsevier. — 96 p.Since its launch in 1996, Drug Discovery Today has been at the cutting edge of the science underpinning drug discovery and development. Drug Discovery Today delivers highly current reviews to the readers, not only addressing the rapid scientific developments in drug discovery associated technologies, but also the management, commercial and regulatory issues that increasingly play a part in how R&D is planned, structured and executed.Contents:
Foundation.
Foundation review: MRI as a tool for evaluation of oral controlled release dosage forms.
Przemyslaw P. Doroz˙yn´ski, Piotr Kulinowski, Anna Mlynarczyk and Greg J. Stanisz.
Keynote.
Fetal hypoxia and programming of matrix metalloproteinases.
Wenni Tong and Lubo Zhang.
Informatics.
The value of in silico chemistry in the safety assessment of chemicals in the consumer goods and pharmaceutical industries.
Sandeep Modi, Michael Hughes, Andrew Garrow and Andrew White.
Post screen.
Mesopore-assisted profi ling strategies in clinical proteomics for drug/target discovery.
Rocco Savino and Rosa Terracciano.
The formulation of polyhedral boranes for the boron neutron capture therapy of cancer.
Gianpiero Calabrese, John J. Nesnas, Eugen Barbu, Dimitris Fatouros and John Tsibouklis.
Liposomal drug formulations in cancer therapy: 15 years along the road.
Marije Slingerland, Henk-Jan Guchelaar and Hans Gelderblom.
Rare disease patient groups as clinical researchers.
Ginger R. Polich.
Biomimetic tissues on a chip for drug discovery.
Amir M. Ghaemmaghami, Matthew J. Hancock, Helen Harrington, Hirokazu Kaji and Ali Khademhosseini.